Kymera Therapeutics annual depreciation and amortization
2019
2020
2021
2022
2023
2024
2025
Kymera Therapeutics Depreciation & Amortization Growth & History (KYMR)
Kymera Therapeutics's depreciation and amortization was $8.3M for fiscal 2025.
View full Kymera Therapeutics company overviewKymera Therapeutics annual depreciation and amortization history
| Fiscal year | Period ended | Depreciation and amortization | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $8.3M | $940,000 | +12.75% |
| 2024 | 2024-12-31 | $7.4M | $3.8M | +106.82% |
| 2023 | 2023-12-31 | $3.6M | $588,000 | +19.75% |
| 2022 | 2022-12-31 | $3.0M | $580,000 | +24.20% |
| 2021 | 2021-12-31 | $2.4M | $634,000 | +35.96% |
| 2020 | 2020-12-31 | $1.8M | $938,000 | +113.70% |
| 2019 | 2019-12-31 | $825,000 | — | — |
Kymera Therapeutics quarterly depreciation and amortization
Q3.19
Q1.20
Q2.20
Q3.20
Q1.21
Q2.21
Q3.21
Q1.22
Q2.22
Q3.22
Q1.23
Q2.23
Q3.23
Q1.24
Q2.24
Q3.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Depreciation and amortization | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $2.0M | −$54,000 | −2.59% |
| Q1 2026 | 2026-03-31 | $2.0M | −$26,000 | −1.27% |
| Q4 2025 | 2025-12-31 | $2.0M | — | — |
| Q3 2025 | 2025-09-30 | $2.1M | $162,000 | +8.15% |
| Q2 2025 | 2025-06-30 | $2.1M | $146,000 | +7.53% |
| Q1 2025 | 2025-03-31 | $2.0M | $587,000 | +40.18% |
| Q3 2024 | 2024-09-30 | $2.0M | $1.1M | +122.01% |
| Q2 2024 | 2024-06-30 | $1.9M | $1.0M | +115.33% |
| Q1 2024 | 2024-03-31 | $1.5M | $582,000 | +66.21% |
| Q3 2023 | 2023-09-30 | $895,000 | $128,000 | +16.69% |
| Q2 2023 | 2023-06-30 | $900,000 | $195,000 | +27.66% |
| Q1 2023 | 2023-03-31 | $879,000 | $192,000 | +27.95% |
| Q3 2022 | 2022-09-30 | $767,000 | $96,000 | +14.31% |
| Q2 2022 | 2022-06-30 | $705,000 | $153,000 | +27.72% |
| Q1 2022 | 2022-03-31 | $687,000 | $202,000 | +41.65% |
| Q3 2021 | 2021-09-30 | $671,000 | $181,000 | +36.94% |
| Q2 2021 | 2021-06-30 | $552,000 | $163,000 | +41.90% |
| Q1 2021 | 2021-03-31 | $485,000 | $98,000 | +25.32% |
| Q3 2020 | 2020-09-30 | $490,000 | $210,000 | +75.00% |
| Q2 2020 | 2020-06-30 | $389,000 | — | — |
| Q1 2020 | 2020-03-31 | $387,000 | — | — |
| Q3 2019 | 2019-09-30 | $280,000 | — | — |
Kymera Therapeutics depreciation and amortization trends
Over the last five fiscal years, Kymera Therapeutics's depreciation and amortization increased from $1.8M to $8.3M, a change of $6.5M. The latest reported quarter, Q2 2026, shows $2.0M.
About the metric
What depreciation and amortization mean
Depreciation and amortization allocate the cost of tangible and intangible assets over their useful lives. These non-cash expenses reduce reported earnings and are commonly added back when calculating EBITDA and operating cash flow.
Calculation and source
Reported depreciation and amortization
TickerStat uses a combined depreciation and amortization value when reported. If a company reports the two components separately for an aligned period, they are added together without duplicating overlapping facts. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Kymera Therapeutics source filings ↗